Brokerages reiterate ‘buy' ratings, raise price targets for Hoya Corporation (7741)
Major brokerages reiterated their "buy" ratings and raised price targets for Hoya Corporation, sending the Japanese optical products and medical technology firm's shares up 5.3% to ¥27,340 on 27 May 2026. The stock is trading ¥1,370 higher than its previous close of ¥25,970.
This upward movement follows positive assessments from Goldman Sachs, Jefferies, Bernstein, and J.P. Morgan. Analysts cited Hoya's robust business execution, high net profit margins, and strong return on equity as key factors. These optimistic outlooks align with the company's fourth-quarter fiscal year 2025 earnings report, released on 30 April 2026, which detailed record consolidated sales and operating profit.
Hoya's strong performance in its information and telecommunications segment, coupled with solid results from its life care business, drove the record quarterly figures. The company's sustained growth in these sectors continues to attract market attention, reflecting investor confidence in its operational capabilities.
Why Analyst Endorsements Are Powering Hoya's Rise
Hoya Corporation operates across two main pillars: information and communication technology, and life care. In the former, they produce essential components like mask blanks for semiconductor manufacturing and glass substrates for hard disk drives. Their life care division focuses on ophthalmic lenses, contact lenses, and medical endoscopes. These products cater to significant global trends, from advancing digitalisation to the growing medical needs of an ageing population, forming the bedrock of Hoya's revenue.
Today's share price surge is directly linked to leading securities analysts reiterating their "buy" ratings and increasing their target prices for Hoya. They have lauded the company's robust business execution, impressive net profit margins, and strong return on equity. This positive outlook follows Hoya's record consolidated sales and operating profit in both its information and communication and life care segments, as detailed in their fourth-quarter 2025 earnings report, released on 30 April 2026. Analysts anticipate this strong performance will persist.
Reflecting these strong analyst endorsements, Hoya's shares are currently trading at ¥27,340, having risen 5.3% from yesterday's close of ¥25,970. This movement indicates the market is now factoring in these heightened expectations for the company's future growth.
Think of it like a highly respected academic journal reviewing a groundbreaking new scientific paper. The journal's editors, who are experts in the field, not only confirm the paper's findings are excellent but also predict its future impact will be even greater than initially thought. This external validation then elevates the paper's standing and influence within the scientific community.
Hoya Corporation
HOYA Corporation (7741) is a diversified global technology and med-tech enterprise. Its life care division manufactures a broad range of optical products, including spectacle and contact lenses, alongside medical equipment such as endoscopes, intraocular lenses, and surgical instruments. This segment also encompasses Eyecity, a specialist contact lens retailer. Beyond healthcare, HOYA is a key supplier of information technology components, producing mask blanks and photomasks for semiconductor and LCD panel manufacturing, as well as glass disks for hard drives. The company also offers imaging products, including optical glass and lenses, and provides digital services like ReadSpeaker speech synthesis software and cloud-based time and attendance (Kinnosuke) and electronic payslip (Yonosuke) solutions. Established in 1941, HOYA Corporation is headquartered in Tokyo, Japan.